scPharmaceuticals Inc.

SCPH

US8106481059

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
4.49 ^USD	+3.22%		-1.54%	-28.39%

Apr. 24	ScPharmaceuticals Inc. Announces First Participant Enrolled in Pivotal Pharmacokinetic Study of Furoscix Auto-Injector (Furosemide 80Mg/Ml) Injection	CI
Mar. 13	Transcript : ScPharmaceuticals Inc., Q4 2023 Earnings Call, Mar 13, 2024

ScPharmaceuticals Inc. Provides Revenue Guidance for the Full Year 2023

January 04, 2024 at 04:05 pm EST

scPharmaceuticals Inc. provided revenue guidance for the full year 2023. For the period, the company anticipates net revenue to be in a range of $13.4 million to $13.6 million.

Latest news about scPharmaceuticals Inc.

ScPharmaceuticals Inc. Announces First Participant Enrolled in Pivotal Pharmacokinetic Study of Furoscix Auto-Injector (Furosemide 80Mg/Ml) Injection	Apr. 24	CI
Transcript : ScPharmaceuticals Inc., Q4 2023 Earnings Call, Mar 13, 2024	Mar. 13
ScPharmaceuticals Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 13	CI
ScPharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 13	CI
ScPharmaceuticals Expects Higher Q4 Product Sales	Jan. 04	MT
ScPharmaceuticals Inc. Provides Revenue Guidance for the Full Year 2023	Jan. 04	CI
Transcript : ScPharmaceuticals Inc., Q3 2023 Earnings Call, Nov 08, 2023	Nov. 08
ScPharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 08	CI
Scpharmaceuticals Announces Positive Feedback from Two Fda Meetings on Key Long-Term Growth Initiatives	23-09-19	CI
ScPharmaceuticals Inc.(NasdaqGS:SCPH) added to S&P Global BMI Index	23-09-18	CI
Craig-Hallum Starts scPharmaceuticals at Buy With $20 Price Target	23-09-07	MT
Transcript : ScPharmaceuticals Inc., Q2 2023 Earnings Call, Aug 10, 2023	23-08-10
ScPharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
ScPharmaceuticals Receives Positive FDA Feedback on Potential Heart Failure Class IV Indication Expansion for Furoscix	23-08-01	MT
ScPharmaceuticals Announces Positive Type C Meeting Feedback from FDA on Potential Heart Failure Class IV Indication Expansion	23-08-01	CI
ScPharmaceuticals Inc.(NasdaqGS:SCPH) added to Russell 3000 Index	23-06-23	CI
ScPharmaceuticals Inc.(NasdaqGS:SCPH) added to Russell 3000E Growth Index	23-06-23	CI
ScPharmaceuticals Inc.(NasdaqGS:SCPH) added to Russell 3000E Index	23-06-23	CI
ScPharmaceuticals Inc.(NasdaqGS:SCPH) added to Russell Small Cap Completeness Index	23-06-23	CI
ScPharmaceuticals Inc.(NasdaqGS:SCPH) added to Russell 2000 Growth Index	23-06-23	CI
ScPharmaceuticals Inc.(NasdaqGS:SCPH) added to Russell 2500 Index	23-06-23	CI
ScPharmaceuticals Inc.(NasdaqGS:SCPH) added to Russell 2000 Index	23-06-23	CI
ScPharmaceuticals Inc.(NasdaqGS:SCPH) dropped from Russell Microcap Value Index	23-06-23	CI
ScPharmaceuticals Inc.(NasdaqGS:SCPH) dropped from Russell 3000E Value Index	23-06-23	CI
ScPharmaceuticals Inc.(NasdaqGS:SCPH) added to Russell 3000 Growth Index	23-06-23	CI

scPharmaceuticals Inc. is a pharmaceutical company. The Company is focused on developing and commercializing products to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The Company develops, internally and through strategic partnerships, products and solutions that aim to expand and advance the outpatient care of select acute conditions. Its lead product candidate, FUROSCIX, consists of its formulation of furosemide delivered via an on-body infuser. FUROSCIX is a formulation of furosemide contained in a pre-filled, Crystal Zenith cartridge and self- administered subcutaneously via a single-use, disposable and wearable on-body delivery system. The Companayâs pipeline programs include SCP-111 (furosemide injection) 80mg/mL is an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home.

Sector

Pharmaceuticals

Calendar

2024-05-07 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for scPharmaceuticals Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

4.49 USD

Average target price

19.5 USD

Spread / Average Target

+334.30%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
SCPHARMACEUTICALS INC.	-28.39%	162M
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B

Other Pharmaceuticals